Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2. The data ...

Moderna announced that its seasonal flu vaccine mRNA-1010 demonstrated 26.6% relative vaccine efficacy compared with standard approved flu vaccines in a phase 3 efficacy trial in adults aged 50 and up ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The mRNA shot stacked up well against a licensed ...

New research from the U.S. Centers for Disease Control and Prevention suggests that people who receive Moderna’s COVID-19 vaccine might experience more side effects than those who get ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...